Cyxone in media
Labiotech: The Rollercoaster of Repurposing an Arthritis Drug for Covid-19
Read the article with CEO Tara Heitner and COO Malin Berthold telling the story how Cyxone initiated the Covid-19 trial. Read the article here.
Read MoreBioStock article: Progress in Q4 sets tone for Cyxone in 2021
BioStock published an article on 24 February 2021 about Cyxone, which can be read in full below. Biotech company Cyxone recently published its fourth quarter result, a period with great focus in the advancement of the project with the...
Read MoreBioStock article: Cyxone’s Covid-19 trial with Rabeximod initiated in Europe
BioStock published an article on 22 January 2021 about Cyxone, which can be read in full below. Last week, the biotech company Cyxone announced that the first patient has been screened in the phase II trial with their candidate...
Read MoreBioStock article: Regulatory approval and up-listing for Cyxone
BioStock published an article on 14 December 2020 about Cyxone, which can be read in full below. Activity is high in Cyxone. The biotechnology company recently received approval to start a phase II study in Poland with Rabeximod in...
Read MoreBioStock article: Cyxone attracts funding and files for new patents
BioStock published an article on 13 November 2020 about Cyxone, which can be read in full below. In a short period of time, biotech company Cyxone has secured some 40 MSEK to fund the phase II study of Rabeximod...
Read MoreBioStock article: Cyxone comments positive toxicological results
BioStock published an article on 10 November 2020 about Cyxone, which can be read in full below. Recently, biotech company Cyxone announced positive results from completed toxicological studies of the drug candidate Rabeximod for treatment of rheumatoid arthritis. The...
Read MoreCyxone ranked top 5 by Startus Insights
Startus Insights ranks Cyxone as one of five top specialty pharma startups impacting the industry. Link to Startus Insights ranking
Read MoreBioStock’s article series on autoimmune disease: Drug Development for RA and MS
BioStock published an article on 4 July 2019 about autoimmune diseases, which can be read in full below. Therapies for autoimmune diseases are available but do not work for all patients, and when they do, side effects can be...
Read MoreArticle in BioStock: World MS Day: Cyxone aims to deliver better, safer treatments to multiple sclerosis patients
BioStock published an article about Cyxone on 29 May 2019, which can be read below. As mainstream MS treatments get scolded by the FDA and the EMA after reports from patients experiencing severe side effects, the market for safer,...
Read MorePharmaceutical Business Review: Cyxone MS drug T20K succeeds in preclinical program
Cyxone MS drug T20K succeeds in preclinical program Cyxone said that T20K, its investigational drug for the treatment of multiple sclerosis (MS), has succeeded in a preclinical program by yielding positive results in the toxicology studies. According to Cyxone,...
Read More